Cargando…

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials

Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knetki-Wróblewska, Magdalena, Kowalski, Dariusz M., Krzakowski, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408765/ https://www.ncbi.nlm.nih.gov/pubmed/32708936 http://dx.doi.org/10.3390/jcm9072273

Ejemplares similares

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Thymic epithelial tumors: Do we know all the prognostic factors?
por: Knetki‐Wróblewska, Magdalena, et al.
Publicado: (2021)

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2020)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2019)

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
por: Olszyna-Serementa, Marta, et al.
Publicado: (2023)

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome
por: Piórek, Aleksandra, et al.
Publicado: (2019)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
por: Waterhouse, David M., et al.
Publicado: (2020)

The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
por: Huang, Jiaxing, et al.
Publicado: (2016)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
por: Borghaei, Hossein, et al.
Publicado: (2021)

A thymoma or not a thymoma—that is the question: a case report
por: Szolkowska, Malgorzata, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
por: Rothwell, Ben, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
por: Gettinger, Scott N., et al.
Publicado: (2021)

Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
por: Abbas, Waseem, et al.
Publicado: (2020)

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2022)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
por: Piórek, Aleksandra, et al.
Publicado: (2022)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer
por: Zhang, Jason, et al.
Publicado: (2019)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
por: Niewada, Maciej, et al.
Publicado: (2023)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
por: Krzakowski, M., et al.
Publicado: (2013)

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas
por: Szpechcinski, Adam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9fjh5aqsjntjekj16b8u7leopi